2023年第3版《NCCN肿瘤临床实践指南：非小细胞肺癌》更新解读

Lung cancer is the malignant tumor with the highest morbidity and mortality in China. Non-small cell lung cancer (NSCLC) is the main pathological subtype of lung cancer. On April 13, 2023, the National Comprehensive Cancer Network (NCCN) released the third edition of the 2023 NCCN Oncology Clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHU, Lingling, WANG, Ting, WU, Juan, ZHAI, Xiaoqian, WU, Qiang, DENG, Hanyu, QIN, Changlong, TIAN, Long, ZHOU, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Guideline Interpretation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365961/
https://www.ncbi.nlm.nih.gov/pubmed/37488078
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.18
Descripción
Sumario:Lung cancer is the malignant tumor with the highest morbidity and mortality in China. Non-small cell lung cancer (NSCLC) is the main pathological subtype of lung cancer. On April 13, 2023, the National Comprehensive Cancer Network (NCCN) released the third edition of the 2023 NCCN Oncology Clinical Practice Guidelines: Non-small Cell Lung Cancer, which reflects the latest advances in international lung cancer research. This article will interpret the main updated contents of the new edition of the guidelines, and compare it with the third edition of the NCCN guidelines in 2022, so as to provide references about the diagnosis and treatment of NSCLC for clinical medical personnel in China.

Ejemplares similares